NCT02962960 - A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

January 22, 2018

Study Completion Date

December 17, 2018

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Anifrolumab

subcutaneous administration every 2 weeks from week 0 to week 50

DRUG

Placebo

subcutaneous administration every two weeks from week 0 to week 50

Trial Locations (14)

Research Site, Debrecen

Research Site, Zalaegerszeg

Research Site, New York

Research Site, Anyang-si

Research Site, Charlotte

Research Site, Orlando

Research Site, Memphis

Research Site, Daegu

Research Site, Busan

Research Site, Gwangju

Research Site, Houston

Research Site, Thousand Oaks

Research Site, Bydgoszcz

Research Site, Warsaw